Long-term safety and efficacy of CART-20 cells in patients with refractory or relapsed B-cell non-Hodgkin lymphoma: 5-years follow-up results of the phase I and IIa trials.

ABSTRACT:

SUBMITTER: Zhang WY 

PROVIDER: S-EPMC5661643 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature